Drug Profile
A-CNDAC
Latest Information Update: 07 Feb 2001
Price :
$50
*
At a glance
- Originator Sankyo
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Feb 2001 Profile reviewed but no significant changes made
- 06 Nov 1997 No-Development-Reported for Cancer in Japan (Unknown route)
- 29 Aug 1996 Preclinical development for Cancer in Japan (Unknown route)